NewAmsterdam Pharma Reports COO Resignation, Advisory Transition

What Happened
NewAmsterdam Pharma Co. N.V. announced (in an 8-K filed July 22, 2026) that Chief Operating Officer Douglas Kling notified the company on July 16, 2026 that he will resign effective August 14, 2026 to become CEO of another clinical-stage biotech. The company expects to enter into a separation agreement and is planning an advisor agreement under which Mr. Kling would provide transition and advisory services related to the PREVAIL clinical trial of obicetrapib and other clinical programs, subject to mutually agreed terms. Material terms will be disclosed in an amendment to the 8-K.

Key Details

• Resignation notice dated July 16, 2026; effective resignation date August 14, 2026.
• Departing executive: Douglas Kling, Chief Operating Officer.
• Kling is leaving to become CEO of another clinical-stage biotech.
• Company expects to negotiate a separation agreement and an advisor agreement to support PREVAIL (obicetrapib) and other clinical programs; terms to be disclosed later.

Why It Matters
A COO departure can affect operational leadership, especially during active clinical programs. The company’s plan to seek an advisory arrangement with Mr. Kling aims to support continuity for the PREVAIL trial and other programs, but final details (including any payments or restrictions) will be disclosed in a forthcoming amendment. Investors should watch for that amendment and any subsequent leadership announcements for more detail on operational continuity and potential costs.